Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach

Fundamental and Clinical Pharmacology

Volumn 28, Issue 4, 2014, Pages 465-471

  Marsot, Amélie ^a   Brevaut Malaty, Véronique ^b   Vialet, Renaud ^b   Boulamery, Audrey ^a   Bruguerolle, Bernard ^a   Simon, Nicolas ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL NORD   (France)

Author keywords

Absolute bioavailability; Paediatrics; Pharmacokinetic; Phenobarbital

Indexed keywords

PHENOBARBITAL; ANTICONVULSIVE AGENT;

ALLOMETRY; ARTICLE; CHILD HOSPITALIZATION; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG INFUSION; FEMALE; HUMAN; INFANT; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; NEWBORN; NEWBORN INTENSIVE CARE; OPTIMAL DRUG DOSE; POPULATION MODEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIMULATION; SUSPENSION; AGE; BIOAVAILABILITY; BIOLOGICAL MODEL; INTRAVENOUS DRUG ADMINISTRATION; NONLINEAR SYSTEM; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; AGE FACTORS; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHENOBARBITAL; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION;

EID: 84904039303     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12042     Document Type: Article

References (15)

1. Sankar J.M., Agarwal R., Deorari A. et al. Management of neonatal seizures. Indian J. Pediatr. (2010) 77 1129-1135.
2. Morselli P.L., Franco-Morselli R., Bossi L. Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications. Clin. Pharmacokinet. (1980) 5 485-527.
3. Alcorn J., McNamara P.J. Pharmacokinetics in the newborn. Adv. Drug Deliv. Rev. (2003) 55 667-686.
4. Johnson T.N. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology (2003) 192 37-48.
5. Grasela T.H. Jr, Donn S.M. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev. Pharmacol. Ther. (1985) 8 374-383.
6. Yukawa E., Suematsu F., Yukawa M. et al. Population pharmacokinetics of phenobarbital by mixed effect modeling using routine clinical pharmacokinetic data in Japanese neonates and infants. J. Clin. Pharm. Ther. (2005) 30 159-163.
7. Yukawa M., Yukawa E., Suematsu F. et al. Population pharmacokinetics of phenobarbital by mixed effect modeling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update. J. Clin. Pharm. Ther. (2011) 36 704-710.
8. Beal S., Sheiner M.E. NONMEM project group. University of California, San Francisco, CA, 1991. (accessed 5 March 2010).
9. Comets E., Brendel K., Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R. Comput. Methods Programs Biomed. (2008) 90 154-166.
10. Anderson B.J., McKee A.D., Holford N.H. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet. (1997) 33 313-327.
11. West G.B., Brown J.H., Enquist B.J. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science (1999) 284 1677-1679.
12. Tomson T., Dahl M.L., Kimland E. Therapeutic monitoring of antiepileptic drugs for epilepsy. Cochrane Database Syst. Rev. (2007) 24 CD002216.
13. Jalling B. Plasma concentrations of phenobarbital in the treatment of seizures in newborns. Acta Paediatr. Scand. (1975) 64 514-524.
14. Viswanathan C.T., Booker H.E., Welling P.G. Bioavailability of oral and intramuscular phenobarbital. J. Clin. Pharmacol. (1978) 18 100-105.
15. Nelson E., Powell J.R., Conrad K. et al. Phenobarbital pharmacokinetics and bioavailability in adults. J. Clin. Pharmacol. (1982) 22 141-148.